An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on ...

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a ...

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

Immune drugmaker TRex Bio has priced a $117 million initial public offering, joining the ranks of nearly two dozen biotechnology companies that have done so in 2026. TRex sold 8,333,334 shares at $14 ...

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...

BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...